📰 Patrick Vermersch News
Page 2 - Patrick Vermersch News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patrick Vermersch. Real-time updates on events, politics, business and more.
September 12, 2023
Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot PARIS, FRANCE / ACCESSWIRE / September 12, 2023 / Ad Scientiam, a global leader in...
December 30, 2022
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis - read this article along with other careers information, tips and advice on BioSpace
December 29, 2022
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS...
October 26, 2022
Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half
October 26, 2022
Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half
October 7, 2022
More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF.
October 6, 2022
THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate
June 24, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
April 13, 2022
DGAP-News: Imcyse SA / Key word(s): Study 13.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement. Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis IMCY-MS-001 study aims to determine safe...
October 5, 2021
Darmstadt: Merck, a science and technology company, has recently announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and...